Neuroendocrine body weight regulation: Integration between fat tissue, gastrointestinal tract, and the brain

Endokrynologia Polska

Volumn 61, Issue 2, 2010, Pages 194-206

  Boguszewski, César Luiz ^a   Paz Filho, Gilberto ^b   Velloso, Licio A ^c  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Biology and Environment   (Australia)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Central nerwous system; Obesity; Pancreas

Indexed keywords

AMYLIN; CHOLECYSTOKININ; ENDOCANNABINOID; ENTEROSTATIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 6; LEPTIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

ADIPOSE TISSUE; BODY WEIGHT; BRAIN; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; INSULIN RELEASE; METABOLIC SYNDROME X; NONHUMAN; NUTRITIONAL DISORDER; OBESITY; PANCREATIC POLYPEPTIDE SECRETING CELL; REVIEW; WEIGHT CONTROL;

ADIPOSE TISSUE; BODY WEIGHT; BRAIN; ENDOCANNABINOIDS; ENERGY METABOLISM; GASTROINTESTINAL TRACT; HUMANS; INSULIN; LEPTIN; MELANOCORTINS; METABOLIC SYNDROME X; NEUROPEPTIDE Y; OBESITY; PANCREAS;

EID: 77953527930     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
2. Morton GJ, Cummings DE, Baskin DG et al. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-295.
3. Wynne K, Stanley S, McGowan B et al. Appetite control. J Endocrinol 2005; 184: 291-318.
4. Horvath TL. The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci 2005; 8: 561-565.
5. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006; 27: 719-727. (Pubitemid 44936055)
6. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13-23.
7. Pagotto U, Marsicano G, Cota D et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100. (Pubitemid 43228239)
8. Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev 2006; 27: 779-793.
9. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004; 10: 563-569.
10. Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.
11. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev 2006; 27: 710-718.
12. Licinio J, Caglayan S, Ozata M et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 2004; 101: 4531-4536. (Pubitemid 38437445)
13. Bluher S, Mantzoros CS. Leptin in humans: lessons from translational research. Am J Clin Nutr 2009; 89: 991S-997S.
14. Ge H, Huang L, Pourbahrami T et al. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem 2002; 277: 45898-45903. (Pubitemid 35417571)
15. Hileman SM, Pierroz DD, Masuzaki H et al. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002; 143: 775-783. (Pubitemid 34164025)
16. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-6096.
17. Hosoi T, Kawagishi T, Okuma Y et al. Brain stem is a direct target for leptin's action in the central nervous system. Endocrinology 2002; 143: 3498-3504. (Pubitemid 34925724)
18. Bjorbaek C, El-Haschimi K, Frantz JD et al. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999; 274: 30059-30065. (Pubitemid 29483389)
19. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-495. (Pubitemid 34436576)
20. Chen K, Li F, Li J et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006; 12: 425-432
21. Rodrigues AM, Radominski RB, Suplicy Hde L et al. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J Clin Endocrinol Metab 2002; 87: 1621-1626
22. Banks WA. Enhanced leptin transport across the blood-brain barrier by alpha 1-adrenergic agents. Brain Res 2001; 899: 209-217. (Pubitemid 32324162)
23. Farooqi IS, Keogh JM, Kamath S et al. Partial leptin deficiency and human adiposity. Nature 2001; 414: 34-35. (Pubitemid 33041612)
24. Paz-Filho G, Volaco A, Suplicy HL et al. Leptin production by the adipose tissue is decreased in obesity associated with severe metabolic syndrome. Arq Bras Endocr Metabol 2009; (in press).
25. Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575 (Pubitemid 29504050)
26. Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am J Clin Nutr 2003; 77: 771-776.
27. Zelissen PM, Stenlof K, Lean ME et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 2005; 7: 755-761. (Pubitemid 41601081)
28. Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105: 7257-7262.
29. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science 2005; 307: 375-379.
30. Bruning JC, Gautam D, Burks DJ et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
31. Obici S, Feng Z, Karkanias G et al. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5: 566-572. (Pubitemid 34568999)
32. Hennige AM, Sartorius T, Tschritter O et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274-1282.
33. Burks DJ, Font de Mora J, Schubert M et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000; 407: 377-382.
34. Saad MJ, Carvalho CR, Thirone AC et al. Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. J Biol Chem 19; 271: 22100-22104.
35. Bence KK, Delibegovic M, Xue B et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006; 12: 917-924. (Pubitemid 44175143)
36. Paz-Filho GJ, Ayala A, Esposito K et al. Effects of leptin on lipid metabolism. Horm Metab Res 2008; 40: 572-574.
37. Larhammar D, Salaneck E: Molecular evolution of NPY receptor subtypes. Neuropeptides 2004; 38: 141-151. (Pubitemid 39158855)
38. Thorsell A, Heilig M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides 2002; 36: 182-193.
39. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006; 27: 736-749.
40. Butler AA, Kesterson RA, Khong K et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000; 141: 3518-3521.
41. Chen AS, Marsh DJ, Trumbauer ME et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26: 97-102.
42. Krude H, Biebermann H, Gruters A. Mutations in the human proopiomelanocortin gene. Ann N Y Acad Sci 2003; 994: 233-239. (Pubitemid 36793872)
43. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006; 27: 762-778. (Pubitemid 44936059)
44. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol 2008; 22: 1023-1031.
45. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866. (Pubitemid 34967064)
46. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737. (Pubitemid 34778727)
47. Coope A, Milanski M, Araújo EP et al. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus. FEBS Lett 2008; 582: 1471-1476.
48. Banerjee RR, Rangwala SM, Shapiro JS et al. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-1198.
49. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212-217. (Pubitemid 30603166)
50. Wallenius K, Jansson JO, Wallenius V. The therapeutic potential of interleukin-6 in treating obesity. Expert Opin Biol Ther 2003; 3: 1061-1070. (Pubitemid 37295762)
51. Moran TH, Dailey MJ. Minireview: Gut peptides: targets for anti-obesity drug development? Endocrinology 2009; 150: 2526-2530.
52. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
53. van der Lely AJ, Tschop M, Heiman ML et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457. (Pubitemid 38780667)
54. Zhang JV, Ren PG, Avsian-Kretchmer O et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-999. (Pubitemid 41611907)
55. Cummings DE, Frayo RS, Marmonier C et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287: E297-304.
56. Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
57. Drazen DL, Vahl TP, D'Alessio DA et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 2006; 147: 23-30.
58. Yildiz BO, Suchard MA, Wong ML et al. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci USA 2004; 101: 10434-10439. (Pubitemid 38924943)
59. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23: 7973-7981. (Pubitemid 37377491)
60. Zigman JM, Nakano Y, Coppari R et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005; 115: 3564-3572. (Pubitemid 43121844)
61. Wortley KE, Anderson KD, Garcia K et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004; 101: 8227-8232. (Pubitemid 38698082)
62. Sun Y, Asnicar M, Saha PK et al. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 2006; 3: 379-386.
63. Challis BG, Coll AP, Yeo GS et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci USA 2004; 101: 4695-4700.
64. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
65. Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controUed trial. Int J Obes (Lond) 2006; 30: 1729-1736. (Pubitemid 44863404)
66. Kogan NM, Mechoulam R. The chemistry of endocannabinoids. J Endocrinol Invest 2006; 29: 3-14.
67. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589. (Pubitemid 40594198)
68. Horvath TL. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 2003; 112: 323-326. (Pubitemid 38063759)
69. Ravinet Trillou C, Delgorge C, Menet C et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648. (Pubitemid 38491158)
70. Scheen AJ, Van Gaal LG, Despres JP et al. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. Rev Med Suisse 2006; 2: 1916-1923.
71. Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 2009; 9: 482-503.